GlassScriptPhysician profile
Melissa M King
NPI 1336340637
$15,420.90
in general payments reported to CMS, 2019-2025
77 companies · $4,661 in 2025
The $4,661 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $132 · 2021: $15.00 · 2022: $1,924 · 2023: $4,118 · 2024: $4,437 · 2025: $4,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,036.18 |
| Education | $180.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,080.48 | 2022-2025 | |
| Janssen Biotech, INC. | $933.20 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Celgene Corporation | $881.50 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $770.98 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $731.30 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $698.48 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $616.93 | 2022-2025 | Opdivo, Opdualag, Pomalyst |
| Genzyme Corporation | $601.79 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $563.00 | 2022-2025 | Libtayo |
| Genentech USA, INC. | $484.79 | 2022-2025 | Polivy, Tecentriq, Columvi |
| Amgen INC. | $460.73 | 2022-2025 | Kyprolis, Nplate, Vectibix |
| Daiichi Sankyo INC. | $437.13 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Lilly USA, LLC | $340.47 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Jazz Pharmaceuticals INC. | $323.52 | 2022-2025 | |
| Abbvie INC. | $295.39 | 2024-2025 |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $295.17 | 2023-2025 | Orserdu, Elzonris |
| Glaxosmithkline, LLC. | $286.30 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Astellas Pharma US INC | $246.98 | 2020-2025 | Padcev, Xtandi, Xospata |
| Takeda Pharmaceuticals U.S.A., INC. | $220.38 | 2022-2025 | Ninlaro, Alunbrig, Cuvitru |
| Pharmaessentia USA Corporation | $216.76 | 2023-2025 | Besremi |
| Array Biopharma INC | $207.28 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Exelixis INC. | $206.76 | 2023-2025 | Cabometyx |
| Seagen INC. | $205.54 | 2022-2023 | Padcev, Tukysa, Adcetris |
| Eisai INC. | $198.95 | 2022-2025 | |
| Sobi, INC | $198.63 | 2022-2025 | |
| Emd Serono, INC. | $194.82 | 2022-2025 | |
| Blueprint Medicines Corporation | $191.40 | 2023-2025 | Ayvakit |
| Incyte Corporation | $191.15 | 2022-2025 | Monjuvi, Zynyz, Pemazyre |
| Pharmacosmos Therapeutics INC. | $186.94 | 2022-2025 | Monoferric |
| Gilead Sciences, INC. | $171.21 | 2022-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $167.92 | 2022-2025 | |
| Coherus Oncology, INC. | $165.53 | 2022-2025 | Loqtorzi |
| Sumitomo Pharma America, INC. | $165.00 | 2023-2025 | Orgovyx |
| Deciphera Pharmaceuticals INC. | $159.06 | 2022-2025 | Qinlock, Romvimza |
| Alexion Pharmaceuticals, INC. | $158.56 | 2023-2025 | Ultomiris |
| Spectrum Pharmaceuticals INC. | $146.40 | 2023-2025 | Rolvedon |
| Beone Medicines USA, INC. | $141.37 | 2025 | Brukinsa, Tevimbra |
| Recordati_rare_diseases_inc. | $130.28 | 2023-2025 | Sylvant, Enjaymo |
| Ipsen Biopharmaceuticals, INC | $128.49 | 2022-2025 | Onivyde, Somatuline Depot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.18 | 2023-2025 | Gilotrif |
| Tersera Therapeutics LLC | $122.64 | 2022-2025 | Quzyttir, Zoladex |
| Aveo Pharmaceuticals, INC. | $107.09 | 2023-2025 | Fotivda |
| Mirati Therapeutics, INC. | $105.80 | 2023-2024 | Krazati |
| Karyopharm Therapeutics INC. | $78.36 | 2023-2025 | Xpovio |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Kyowa Kirin, INC. | $63.59 | 2025 | |
| Puma Biotechnology, INC. | $61.95 | 2022-2025 | |
| Heron Therapeutics, INC. | $59.90 | 2022 | |
| Genmab U.S., INC. | $59.89 | 2023-2025 | Epkinly |
| Springworks Therapeutics, INC. | $55.64 | 2024-2025 | Ogsiveo |
| Sun Pharmaceutical Industries INC. | $52.59 | 2024-2025 | |
| Caris Mpi, INC. | $47.87 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $46.52 | 2022-2025 | |
| Adaptive Biotechnologies Corporation | $45.72 | 2022-2023 | Clonoseq |
| Beigene USA, INC. | $38.14 | 2022-2025 | Brukinsa |
| Celltrion USA INC. | $37.60 | 2025 | Vegzelma |
| Acrotech Biopharma INC. | $36.16 | 2024-2025 | Beleodaq |
| Iovance Biotherapeutics, INC. | $35.85 | 2024-2025 | Amtagvi |
| Amneal Pharmaceuticals LLC | $32.64 | 2024-2025 | Alymsys, Avastin |
| Janssen Scientific Affairs, LLC | $29.73 | 2023 | Tecvayli |
| Rigel Pharmaceuticals, INC. | $27.06 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Syndax Pharmaceuticals, INC. | $26.54 | 2025 | |
| Tempus Ai, INC | $25.71 | 2025 | Xt Cdx |
| Pharming Healthcare, INC. | $23.33 | 2023 | Ruconest |
| Progenics Pharmaceuticals, INC. | $19.92 | 2023 | Pylarify |
| Adc Therapeutics America, INC. | $19.06 | 2023 | |
| Paratek Pharmaceuticals, INC. | $18.56 | 2023 | Nuzyra |
| Csl Behring | $17.31 | 2024 | Hizentra |
| Morphosys, US INC. | $16.67 | 2023 | Monjuvi |
| G1 Therapeutics, INC. | $16.03 | 2022 | |
| Mission Pharmacal Company | $15.00 | 2021 | |
| Verity Pharmaceuticals INC. | $14.90 | 2023 | Trelstar |
| Apellis Pharmaceuticals, INC. | $14.51 | 2025 | Empaveli |
| Immunogen, INC. | $14.38 | 2024 | Elahere |
| Fennec Pharmaceuticals, INC. | $14.21 | 2025 | Fyarro |
| Myovant Sciences INC. | $12.22 | 2022 | |
| Eusa Pharma (US) LLC | $12.07 | 2022 |
Drugs and devices associated with these payments
Reblozyl $605Keytruda $578Libtayo $490Enhertu $404Opdivo $368Orgovyx $340Kisqali $332Zepzelca $305Darzalex $297Xtandi $283Lynparza $282Orserdu $281Jaypirca $277Calquence $252Padcev $249Tecvayli $245Verzenio $234Ayvakit $220Talvey $219Besremi $217Cabometyx $207Imbruvica $198Sarclisa $191Erleada $187Venclexta $183Retevmo $180Imfinzi $175Lenvima $171Braftovi $160Monjuvi $160Ultomiris $159Monoferric $158Polivy $158Scemblix $157Brukinsa $151Ojjaara $149Rolvedon $146Mektovi $143Epkinly $133Enjaymo $128Pomalyst $127Udenyca $123Krazati $122Jemperli $121Fabhalta $119Lorbrena $119Stivarga $119Vitrakvi $119Sylvant $116Carvykti $115Qinlock $115Pluvicto $115Balversa $114Ninlaro $112Onivyde $111Fotivda $107Tukysa $105Akeega $101Elahere $101Tecentriq $99.96Opdualag $95.20Columvi $89.90Zejula $89.54Rybrevant $87.06Nubeqa $83.04Xpovio $78.36Doptelet $78.30Paxlovid $77.33Comirnaty $77.33Mekinist $75.54Lunsumio $74.80Welireg $73.99Datroway $71.22Quzyttir $70.90Elitek $69.99Trodelvy $69.75Vonjo $68.69Zynyz $66.52Piqray $64.06Poteligeo $63.59Phesgo $60.71Promacta $60.14Talzenna $59.09Kyprolis $57.98Pemazyre $57.53Xalkori $56.33Ogsiveo $55.64Odomzo $52.59Inlyta $50.27Nerlynx $50.25Cablivi $49.75Romvimza $49.59Mi Cancer Seek $47.87Gilotrif $44.37Loqtorzi $44.14Vectibix $43.12Nplate $43.12Xgeva $43.12Alprolix $41.51Altuviiio $41.51
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.